Login
Taysha Gene Therapies, Inc. logo

Taysha Gene Therapies, Inc.

tayshagtx.com

What Do They Do?

Develops gene therapies for severe genetic diseases of the central nervous system, with a treatment in development for Rett syndrome.

How Do They Make Money?

Revenue comes from activities under the Astellas Transactions, including an exclusive option to license intellectual property and research and development work.

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $109M in FY2025.

Operating income, FY2025
−1131% of revenue
▼ −21% (Loss) vs FY2024 (−$91.5M, −1098%)
Net income, FY2025
−1115% of revenue
▼ −22% (Loss) vs FY2024 (−$89.3M, −1072%)
Free cash flow, FY2025
−960% of revenue
▼ −15% (Loss) vs FY2024 (−$81.6M, −979%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
Net income
▼ −20% (Loss)
vs −$32.7M in Q3 FY2025

A narrower pipeline focus The older report described candidates for giant axonal neuropathy and other neurological conditions; the latest centers on Rett syndrome and frames the rest of its central nervous system pipeline as future opportunities.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support